Lead Product(s) : GRAd-HIV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Ragon Institute
Deal Size : Undisclosed
Deal Type : Collaboration
ReiThera Srl, Ragon Institute and IAVI Collaborate to Advance T Cell HIV Vaccine
Details : The collaboration aims to develop a novel HIV vaccine candidate that will be composed of ReiThera’s Gorilla adenoviral vector (GRAd) and HIV T cell epitopes identified by the Ragon Institute.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : GRAd-HIV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Ragon Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Antios Therapeutics
Deal Size : $50.0 million
Deal Type : Acquisition
Details : Under the agreement, Antios will purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) which is being developed for the treatment of HBV.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Antios Therapeutics
Deal Size : $50.0 million
Deal Type : Acquisition
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Applied DNA Sciences Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Applied DNA and Takis Biotech partner on coronavirus vaccine
Details : LineaRx, a subsidiary of Applied DNA, will work with Takis Biotech on preclinical development of a linear DNA vaccine based on polymerase chain reaction (PCR).
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Applied DNA Sciences Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Applied DNA Sciences Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : All animals demonstrated seroconversion to producing IgG against SARS-CoV-2 Spike Protein already by day 14, and significantly enhanced responses by day 38.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 17, 2020
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Applied DNA Sciences Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takis Vaccines Neutralize SARS-CoV-2
Details : Researchers at National Institute of Infectious Diseases found that Takis vaccines after a single vaccination developed antibodies in mice that can block the infection of SARS-CoV-2 on human cells.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 05, 2020
Lead Product(s) : DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-eVax
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Rottapharm Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of this collaboration, Rottapharm Biotech will provide Takis with operational support, and with the financial resources needed to complete Phase I/II clinical trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $3.3 million
April 06, 2020
Lead Product(s) : COVID-eVax
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Rottapharm Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
After The USA And Australia, The First Pre-Clinical Animal Tests Are Also Carried Out In Italy
Details : The vaccine developed by ReiThera has been obtained from a fragment of the genetic material of the virus and is based on the technology called electroporation.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Applied DNA Sciences Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Applied DNA is expected to enter large-scale production of candidates in march; preclinical testing in animals by takis biotech anticipated to begin in calendar Q2 2020.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 03, 2020
Lead Product(s) : Linear DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Applied DNA Sciences Inc
Deal Size : Undisclosed
Deal Type : Collaboration